MarketBeat
16 Oct 2026, 01:02 UTC · 2h ago
Impact · against what's priced in
PDSB is a strong buy on the reporting of a 70% ORR for PDS0301 in a heavily pretreated population, which vastly outperforms the 2.5% industry benchmark. The immediate catalysts are the FDA protocol submission this quarter and the presentation of survival data in March.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
PDS0301 combined with hepatic artery infusion showed a 70% objective response rate at six months versus 35% for the comparator cohort.
Newdisclosed during virtual key opinion leader event
So whatThis represents a ~28x increase over the 2.5% average ORR cited for typical third- and fourth-line experimental arms.
More positive than 99% of claims this week
Continue reading
5 related stories
The reporting of a 70% ORR at six months compared to a 35% comparator—and a 2.5% general benchmark—provides a high-conviction signal for PDS0301. The commitment to a Phase III protocol submission this quarter and survival data in March creates a concrete timeline for value realization.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
PDS Biotechnology plans to submit a Phase III protocol to the FDA during the current quarter with a target trial start in Q1 2027.
Newstated as current quarter plan in article
More positive than 88% of claims this week
Updated survival data for PDS0301 will be presented at the Society of Surgical Oncology annual meeting in March.
Newannounced presentation date in March
So whatThis creates a high-volatility catalyst event within the next 5 months to validate the ORR data.
More positive than 81% of claims this week
The company expects to report maturing results from PDS0301 programs across several tumor types over the next 6 to 18 months.
Newdisclosed as future reporting timeline
More positive than 68% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company reported positive Phase II results with higher response rates and is advancing its lead candidate PDS0301 into Phase III studies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
13h ago
—
PDSB hasn't traded since this ran. Last close $1.30 (Oct 15); the reaction starts at the next open.
PDSB chart →
